Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease

Abstract Background The search for biomarkers suitable for early diagnosis of Crohn's disease (CD) is challenging. This study investigated the efficacy of serological markers for the early diagnosis of CD. Methods This was a retrospective nested cohort study. Indirect immunofluorescence and enz...

Full description

Saved in:
Bibliographic Details
Main Authors: Xianzong Ma, Wenyu Zhang, Xin Wang, Lang Yang, Juan Jiao, Yan Jia, Dezhi Wang, Junfeng Xu, Peng Jin, Mingjie Zhang, Shirong Li, Yuanming Pan, Jianqiu Sheng
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:iLabmed
Subjects:
Online Access:https://doi.org/10.1002/ila2.28
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849394001920131072
author Xianzong Ma
Wenyu Zhang
Xin Wang
Lang Yang
Juan Jiao
Yan Jia
Dezhi Wang
Junfeng Xu
Peng Jin
Mingjie Zhang
Shirong Li
Yuanming Pan
Jianqiu Sheng
author_facet Xianzong Ma
Wenyu Zhang
Xin Wang
Lang Yang
Juan Jiao
Yan Jia
Dezhi Wang
Junfeng Xu
Peng Jin
Mingjie Zhang
Shirong Li
Yuanming Pan
Jianqiu Sheng
author_sort Xianzong Ma
collection DOAJ
description Abstract Background The search for biomarkers suitable for early diagnosis of Crohn's disease (CD) is challenging. This study investigated the efficacy of serological markers for the early diagnosis of CD. Methods This was a retrospective nested cohort study. Indirect immunofluorescence and enzyme‐linked immunosorbent assay were used to detect ASCA IgG, ASCA IgA, AYMA IgG, AYCA IgG, FI2Y IgG, p‐ANCA IgG, GAB IgG and PAB IgG in patient serum samples. Results The positive rates of ASCA IgG, ASCA IgA, AYMA IgG, AYCA IgG, FI2Y IgG, p‐ANCA IgG, GAB IgG and PAB IgG in patients with early CD, advanced CD and other intestinal diseases were 37.0% versus 56.8% versus 27.8%; 3.7% versus 20.5% versus 19.4%; 14.8% versus 2.3% versus 2.8%; 25.9% versus 9.1% versus 8.3%; 18.5% versus 15.9% versus 8.3%; 0.0% versus 2.8%, 18.5%; 13.6% versus 18.2% versus 16.7%; and 7.4% versus 20.5% versus 0.0%, respectively. The positive rates of ASCA IgG, AYCA IgG and PAB IgG were significantly different among the three groups (p < 0.05). In 85.2% of early CD patients, at least one antibody was detected 1 year before diagnosis. The sensitivity of the ASCA/AYMA/AYCA/FI2Y/GAB combination for early diagnosis was 85.2%. The sensitivity of the ASCA/AYMA/AYCA/FI2Y/GAB/PAB/PANCA combination for differentiating CD from other diseases was 87.3%. Conclusions ASCA IgG and AYCA IgG have potential value in identifying the course of CD. AYCA IgG may be a potential marker for the early diagnosis of CD, and ASCA IgG indicates an advanced stage. The combination of ASCA, AYMA, AYCA, FI2Y, and GAB improves early diagnostic accuracy of CD.
format Article
id doaj-art-29cea375af05499d8f9e617f29db0fc0
institution Kabale University
issn 2834-443X
2834-4448
language English
publishDate 2023-12-01
publisher Wiley
record_format Article
series iLabmed
spelling doaj-art-29cea375af05499d8f9e617f29db0fc02025-08-20T03:40:13ZengWileyiLabmed2834-443X2834-44482023-12-011318118910.1002/ila2.28Clinical validation of serum immunosignatures in early diagnosis of Crohn's diseaseXianzong Ma0Wenyu Zhang1Xin Wang2Lang Yang3Juan Jiao4Yan Jia5Dezhi Wang6Junfeng Xu7Peng Jin8Mingjie Zhang9Shirong Li10Yuanming Pan11Jianqiu Sheng12Medical School of Chinese PLA Chinese PLA General Hospital Beijing ChinaCapital Medical University Beijing ChinaDepartment of Gastroenterology The Seventh Medical Center of Chinese PLA General Hospital Beijing ChinaDepartment of Gastroenterology The Seventh Medical Center of Chinese PLA General Hospital Beijing ChinaLaboratory Medicine Center The Seventh Medical Center of Chinese PLA General Hospital Beijing ChinaDepartment of Gastroenterology The Seventh Medical Center of Chinese PLA General Hospital Beijing ChinaMedical School of Chinese PLA Chinese PLA General Hospital Beijing ChinaSenior Department of Gastroenterology The First Medical Center of Chinese PLA General Hospital Beijing ChinaDepartment of Gastroenterology The Seventh Medical Center of Chinese PLA General Hospital Beijing ChinaDepartment of Gastroenterology The Seventh Medical Center of Chinese PLA General Hospital Beijing ChinaDepartment of Gastroenterology The Seventh Medical Center of Chinese PLA General Hospital Beijing ChinaCancer Research Center Beijing Chest Hospital Capital Medical University Beijing ChinaMedical School of Chinese PLA Chinese PLA General Hospital Beijing ChinaAbstract Background The search for biomarkers suitable for early diagnosis of Crohn's disease (CD) is challenging. This study investigated the efficacy of serological markers for the early diagnosis of CD. Methods This was a retrospective nested cohort study. Indirect immunofluorescence and enzyme‐linked immunosorbent assay were used to detect ASCA IgG, ASCA IgA, AYMA IgG, AYCA IgG, FI2Y IgG, p‐ANCA IgG, GAB IgG and PAB IgG in patient serum samples. Results The positive rates of ASCA IgG, ASCA IgA, AYMA IgG, AYCA IgG, FI2Y IgG, p‐ANCA IgG, GAB IgG and PAB IgG in patients with early CD, advanced CD and other intestinal diseases were 37.0% versus 56.8% versus 27.8%; 3.7% versus 20.5% versus 19.4%; 14.8% versus 2.3% versus 2.8%; 25.9% versus 9.1% versus 8.3%; 18.5% versus 15.9% versus 8.3%; 0.0% versus 2.8%, 18.5%; 13.6% versus 18.2% versus 16.7%; and 7.4% versus 20.5% versus 0.0%, respectively. The positive rates of ASCA IgG, AYCA IgG and PAB IgG were significantly different among the three groups (p < 0.05). In 85.2% of early CD patients, at least one antibody was detected 1 year before diagnosis. The sensitivity of the ASCA/AYMA/AYCA/FI2Y/GAB combination for early diagnosis was 85.2%. The sensitivity of the ASCA/AYMA/AYCA/FI2Y/GAB/PAB/PANCA combination for differentiating CD from other diseases was 87.3%. Conclusions ASCA IgG and AYCA IgG have potential value in identifying the course of CD. AYCA IgG may be a potential marker for the early diagnosis of CD, and ASCA IgG indicates an advanced stage. The combination of ASCA, AYMA, AYCA, FI2Y, and GAB improves early diagnostic accuracy of CD.https://doi.org/10.1002/ila2.28Crohn's diseaseearly diagnosisserological markersAYCAASCA
spellingShingle Xianzong Ma
Wenyu Zhang
Xin Wang
Lang Yang
Juan Jiao
Yan Jia
Dezhi Wang
Junfeng Xu
Peng Jin
Mingjie Zhang
Shirong Li
Yuanming Pan
Jianqiu Sheng
Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease
iLabmed
Crohn's disease
early diagnosis
serological markers
AYCA
ASCA
title Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease
title_full Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease
title_fullStr Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease
title_full_unstemmed Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease
title_short Clinical validation of serum immunosignatures in early diagnosis of Crohn's disease
title_sort clinical validation of serum immunosignatures in early diagnosis of crohn s disease
topic Crohn's disease
early diagnosis
serological markers
AYCA
ASCA
url https://doi.org/10.1002/ila2.28
work_keys_str_mv AT xianzongma clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT wenyuzhang clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT xinwang clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT langyang clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT juanjiao clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT yanjia clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT dezhiwang clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT junfengxu clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT pengjin clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT mingjiezhang clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT shirongli clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT yuanmingpan clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease
AT jianqiusheng clinicalvalidationofserumimmunosignaturesinearlydiagnosisofcrohnsdisease